Literature DB >> 31922665

Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics.

Jose de Leon1, Emilio J Sanz2, G Niklas Norén3, Carlos De Las Cuevas4.   

Abstract

Entities:  

Year:  2020        PMID： 31922665      PMCID： PMC6953557          DOI： 10.1002/wps.20707

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  8 in total

1.  Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine.

Authors:  Jonathan G Leung; M Earth Hasassri; Jason N Barreto; Sarah Nelson; Robert J Morgan
Journal:  Psychosomatics       Date:  2016-11-18       Impact factor: 2.386

2.  Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study.

Authors:  C Rohde; C Polcwiartek; K Kragholm; B H Ebdrup; D Siskind; J Nielsen
Journal:  Acta Psychiatr Scand       Date:  2017-10-24       Impact factor: 6.392

3.  Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months.

Authors:  Zachary R Stoecker; Wales T George; Jeffrey B O'Brien; Jon Jancik; Eduardo Colon; Joseph J Rasimas
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

Review 4.  Elevated clozapine levels associated with infection: A systematic review.

Authors:  Scott R Clark; Nicola S Warren; Gajin Kim; David Jankowiak; Klaus Oliver Schubert; Steve Kisely; Tori Forrester; Bernhard T Baune; Dan J Siskind
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

Review 5.  A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults.

Authors:  Giuseppe Cicala; Maria Antonietta Barbieri; Edoardo Spina; Jose de Leon
Journal:  Expert Rev Clin Pharmacol       Date:  2019-02-08       Impact factor: 5.045

6.  Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study.

Authors:  Galen Chin-Lun Hung; Hsing-Cheng Liu; Shu-Yu Yang; Chun-Hung Pan; Ya-Tang Liao; Chiao-Chicy Chen; Chian-Jue Kuo
Journal:  J Clin Psychiatry       Date:  2016-01       Impact factor: 4.384

7.  Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.

Authors:  David M Taylor; Petrina Douglas-Hall; Banke Olofinjana; Eromona Whiskey; Arwel Thomas
Journal:  Br J Psychiatry       Date:  2009-02       Impact factor: 9.319

8.  Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years.

Authors:  Jentien M Vermeulen; Geeske van Rooijen; Marita P J van de Kerkhof; Arjen L Sutterland; Christoph U Correll; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306
  8 in total
  15 in total

1.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

2.  The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services.

Authors:  Thomas R E Barnes; James H MacCabe; John M Kane; Oriana Delgado; Carol Paton
Journal:  Ther Adv Psychopharmacol       Date:  2020-08-06

Review 3.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

4.  Consensus statement on the use of clozapine during the COVID-19 pandemic.

Authors:  Dan Siskind; William G Honer; Scott Clark; Christoph U Correll; Alkomiet Hasan; Oliver Howes; John M Kane; Deanna L Kelly; Robert Laitman; Jimmy Lee; James H MacCabe; Nick Myles; Jimmi Nielsen; Peter F Schulte; David Taylor; Helene Verdoux; Amanda Wheeler; Oliver Freudenreich
Journal:  J Psychiatry Neurosci       Date:  2020-05-01       Impact factor: 6.186

Review 5.  Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

Authors:  Giovanni Ostuzzi; Davide Papola; Chiara Gastaldon; Georgios Schoretsanitis; Federico Bertolini; Francesco Amaddeo; Alessandro Cuomo; Robin Emsley; Andrea Fagiolini; Giuseppe Imperadore; Taishiro Kishimoto; Giulia Michencigh; Michela Nosé; Marianna Purgato; Serdar Dursun; Brendon Stubbs; David Taylor; Graham Thornicroft; Philip B Ward; Christoph Hiemke; Christoph U Correll; Corrado Barbui
Journal:  BMC Med       Date:  2020-07-15       Impact factor: 8.775

Review 6.  Psychopharmacology of COVID-19.

Authors:  Melanie Bilbul; Patricia Paparone; Anna M Kim; Shruti Mutalik; Carrie L Ernst
Journal:  Psychosomatics       Date:  2020-05-18       Impact factor: 2.386

7.  No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan.

Authors:  Masahiro Hata; Michiko Fujimoto; Koji Kanai; Kenji Yoshiyama; Yoshitaka Nakatani; Daiji Nakabayashi; Saki Maemura; Shinya Kawata; Takaaki Hakozaki; Shuya Nishikura; Aiko Umemoto; Toru Sasada; Kazuhiko Iwata; Hideki Tanaka; Akiko Mamoto; Yuuki Toi; Norio Taniguchi; Makiko Saito; Yoshio Kimura; Kazuko Kishimoto; Megumi Hayami; Manabu Ikeda
Journal:  Neuropsychopharmacol Rep       Date:  2021-02-19

8.  Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; John M Kane; Christoph Hiemke; Michael Paulzen; Ekkehard Haen
Journal:  Clin Pharmacokinet       Date:  2020-10-01       Impact factor: 6.447

Review 9.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

Review 10.  A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43.

Authors:  Motohiro Okada; Kouji Fukuyama; Takashi Shiroyama; Masahiko Murata
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.